文献速递神经肿瘤

非中线部位H3K27M突变弥漫性胶质瘤的特征

Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
PubMed 文献 · J Neurooncol · 2024-06-27

本研究回顾本机构2016至2023年诊断为H3K27M突变弥漫性胶质瘤的51例患者(18例儿童、33例成人),发现2例(4%)为非中线部位,并结合文献共39例非中线H3K27M突变弥漫性胶质瘤分析。此类肿瘤多见于颞叶(48%)、青少年及成人,中位总生存期10.3个月(0.1-84),常伴TP53突变(74%)、ATRX突变(71%)及PDGFRA突变或扩增(44%),DNA甲基化分析聚类于或邻近H3K27M突变弥漫性中线胶质瘤参考组,作者认为其可能为这类肿瘤的罕见解剖部位表现,或可从ONC201等新治疗中获益。

要点

  • 非中线H3K27M突变弥漫性胶质瘤多见于颞叶(48%),中位诊断年龄19.1岁,预后差,中位总生存期10.3个月(0.1-84)。
  • 非中线H3K27M突变弥漫性胶质瘤常伴TP53突变(74%)、ATRX突变(71%)及PDGFRA突变或扩增(44%)。
  • DNA甲基化分析显示非中线H3K27M突变弥漫性胶质瘤聚类于或邻近H3K27M突变弥漫性中线胶质瘤参考组,作者认为其或可从ONC201等新治疗中获益。

核心结论

  • 非中线H3K27M突变弥漫性胶质瘤与中线 counterpart 有许多相似之处,提示其可能为这类肿瘤的罕见解剖部位表现,作者认为其或可从ONC201等新治疗中获益。

研究设计与样本

  • 回顾本机构2016至2023年诊断为H3K27M突变弥漫性胶质瘤的患者临床、影像及组织学特征,识别非中线部位病例,并对非中线H3K27M突变弥漫性胶质瘤进行分子特征分析(DNA甲基化谱、全基因组和转录组测序或靶向测序),同时复习既往报道病例。
  • 本机构共51例患者(18例儿童、33例成人)诊断为H3K27M突变弥漫性胶质瘤,其中2例(4%)为非中线部位;结合文献共39例非中线H3K27M突变弥漫性胶质瘤。

主要发现

  • 非中线H3K27M突变弥漫性胶质瘤最常位于颞叶(48%),多见于青少年及成人,预后差,中位总生存期10.3个月(0.1-84),中位诊断年龄19.1岁。
  • 非中线H3K27M突变弥漫性胶质瘤常见TP53突变(74%)、ATRX突变(71%)及PDGFRA突变或扩增(44%)。
  • DNA甲基化分析显示非中线H3K27M突变弥漫性胶质瘤聚类于或邻近H3K27M突变弥漫性中线胶质瘤参考组。
  • 与中线 counterpart 相比,非中线H3K27M突变胶质瘤似乎更常伴PDGFRA改变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diffuse midline gliomas (DMG) with H3K27 alterations (H3K27M-DMG) are a highly aggressive form of brain cancer. In rare cases, H3K27 mutations have been observed in diffuse non-midline gliomas (DNMG). It is currently unclear how these tumors should be classified. Herein, we analyze the characteristics of DNMG with H3K27M mutations. METHODS: We reviewed the clinical, radiological and histological characteristics of all patients with an H3K27M mutated diffuse glioma diagnosed in our institution, between 2016 and 2023, to identify cases with a non-midline location. We then performed a molecular characterization (DNA methylation profiling, whole genome and transcriptome sequencing or targeted sequencing) of patients with an H3K27M-mutant DNMG and reviewed previously reported cases. RESULTS: Among 51 patients (18 children and 33 adults) diagnosed with an H3K27M diffuse glioma, we identified two patients (4%) who had a non-midline location. Including our two patients, 39 patients were reported in the literature with an H3K27M-mutant DNMG. Tumors were most frequently located in the temporal lobe (48%), affected adolescents and adults, and were associated with a poor outcome (median overall survival was 10.3 months (0.1-84)). Median age at diagnosis was 19.1 years. Tumors frequently harbored TP53 mutations (74%), ATRX mutations (71%) and PDGFRA mutations or amplifications (44%). In DNA methylation analysis, H3K27M-mutant DNMG clustered within or close to the reference group of H3K27M-mutant DMG. Compared to their midline counterpart, non-midline gliomas with H3K27M mutations seemed more frequently associated with PDGFRA alterations. CONCLUSION: DNMG with H3K27M mutations share many similarities with their midline counterpart, suggesting that they correspond to a rare anatomical presentation of these tumors. This is of paramount importance, as they may benefit from new therapeutic approaches such as ONC201.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Guidara S, Seyve A, Poncet D, et al. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location. J Neurooncol. 2024. PMID: 38937309. doi:10.1007/s11060-024-04733-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。